SCUELJapan healthcare data

Home › Japan pharmaceutical market

Japan market size

Japan pharmaceutical market

医薬品の市場

Japan's prescription drug market was an estimated ¥10.36 trillion in FY2024 (April 2024–March 2025), -0.5% year on year and +1.3% a year on average over the last three years. Browse 100 molecules and 23 drug classes below; each page shows ten years of value and growth compared with related drugs.

¥10.36tnValue FY2024 (est.)
-0.5%Year on year
+1.3%3-year average growth

Drug classes

Molecules grouped by mechanism of action.

ACE inhibitorsACE阻害薬Alpha-1 blockers for BPH前立腺肥大症のα1遮断薬Alpha-2-delta ligands for neuropathic pain神経障害性疼痛の治療薬（α2δリガンド）Alpha-glucosidase inhibitorsα-グルコシダーゼ阻害薬Angiotensin II receptor blockers (ARBs)ARB（アンジオテンシンII受容体拮抗薬）Anti-herpesvirus agents抗ヘルペスウイルス薬Anti-influenza agents抗インフルエンザ薬BisphosphonatesビスホスホネートDPP-4 inhibitorsDPP-4阻害薬Dihydropyridine calcium channel blockersCa拮抗薬（ジヒドロピリジン系）Direct oral anticoagulants (DOACs)DOAC（直接経口抗凝固薬）Fibratesフィブラート系薬Glinidesグリニド薬H2 receptor antagonistsH2受容体拮抗薬Long-acting (basal) insulins持効型インスリンOmega-3 fatty acid agents多価不飽和脂肪酸製剤Proton pump inhibitors and P-CABsPPI・P-CABRapid-acting insulins超速効型インスリンSGLT2 inhibitorsSGLT2阻害薬StatinsスタチンSulfonylureasスルホニル尿素薬（SU薬）TNF inhibitorsTNFα阻害薬Xanthine oxidase inhibitors尿酸生成抑制薬

Molecules

The largest molecules by prescription value with a Japanese Accepted Name, in alphabetical order.

Abatacept (Genetical Recombination)アバタセプト（遺伝子組換え）AbemaciclibアベマシクリブAbiraterone Acetateアビラテロン酢酸エステルAcetaminophenアセトアミノフェンAdalimumab (Genetical Recombination)アダリムマブ（遺伝子組換え）Aflibercept (Genetical Recombination)アフリベルセプト（遺伝子組換え）Alectinib Hydrochlorideアレクチニブ塩酸塩Amlodipine Besilateアムロジピンベシル酸塩ApixabanアピキサバンAtezolizumab (Genetical Recombination)アテゾリズマブ（遺伝子組換え）AzilsartanアジルサルタンBaricitinibバリシチニブBevacizumab (Genetical Recombination)ベバシズマブ（遺伝子組換え）Bictegravir Sodium / Emtricitabine / Tenofovir Alafenamide Fumarateビクテグラビルナトリウム・エムトリシタビン・テノホビル　アラフェナミドフマル酸塩BilastineビラスチンBrexpiprazoleブレクスピプラゾールDapagliflozinダパグリフロジンDaratumumab (Genetical Recombination) / Vorhyaluronidase Alfa (Genetical Recombination)ダラツムマブ（遺伝子組換え）・ボルヒアルロニダーゼ　アルファ（遺伝子組換え）Denosumab (Genetical Recombination)デノスマブ（遺伝子組換え）Drospirenone / Ethinylestradiol Betadexドロスピレノン・エチニルエストラジオール　ベータデクスDupilumab (Genetical Recombination)デュピルマブ（遺伝子組換え）Durvalumab (Genetical Recombination)デュルバルマブ（遺伝子組換え）Edoxaban Tosilate Hydrateエドキサバントシル酸塩水和物EldecalcitolエルデカルシトールEltrombopag Olamineエルトロンボパグ　オラミンEmicizumab (Genetical Recombination)エミシズマブ（遺伝子組換え）EmpagliflozinエンパグリフロジンEmpagliflozin / Linagliptinエンパグリフロジン・リナグリプチンEnsitrelvir Fumaric Acidエンシトレルビル　フマル酸EnzalutamideエンザルタミドEpcoritamab (Genetical Recombination)エプコリタマブ（遺伝子組換え）Epinastine Hydrochlorideエピナスチン塩酸塩Esomeprazole Magnesium Hydrateエソメプラゾールマグネシウム水和物Faricimab (Genetical Recombination)ファリシマブ（遺伝子組換え）Fexofenadine Hydrochlorideフェキソフェナジン塩酸塩Fluticasone Furoate / Umeclidinium Bromide / Vilanterol Trifenatateフルチカゾンフランカルボン酸エステル・ウメクリジニウム臭化物・ビランテロールトリフェニル酢酸塩Golimumab (Genetical Recombination)ゴリムマブ（遺伝子組換え）Guanfacine Hydrochlorideグアンファシン塩酸塩Infliximab (Genetical Recombination)インフリキシマブ（遺伝子組換え）KetoprofenケトプロフェンL-CarbocisteineＬ－カルボシステインLacosamideラコサミドLemborexantレンボレキサントLenalidomideレナリドミドLeuprorelin Acetateリュープロレリン酢酸塩LevetiracetamレベチラセタムLinagliptinリナグリプチンLoxoprofen Sodium Hydrateロキソプロフェンナトリウム水和物LubiprostoneルビプロストンMacitentanマシテンタンMagnesium Oxide酸化マグネシウムMepolizumab (Genetical Recombination)メポリズマブ（遺伝子組換え）MesalazineメサラジンMetformin Hydrochlorideメトホルミン塩酸塩MirabegronミラベグロンMirogabalin Besilateミロガバリンベシル酸塩MolnupiravirモルヌピラビルMontelukast SodiumモンテルカストナトリウムNintedanib Ethanesulfonateニンテダニブエタンスルホン酸塩Nivolumab (Genetical Recombination)ニボルマブ（遺伝子組換え）OlaparibオラパリブOsimertinib Mesilateオシメルチニブメシル酸塩PaclitaxelパクリタキセルPalbociclibパルボシクリブPanitumumab (Genetical Recombination)パニツムマブ（遺伝子組換え）PemafibrateペマフィブラートPembrolizumab (Genetical Recombination)ペムブロリズマブ（遺伝子組換え）Pertuzumab (Genetical Recombination)ペルツズマブ（遺伝子組換え）Pertuzumab (Genetical Recombination) / Trastuzumab (Genetical Recombination) / Vorhyaluronidase Alfa (Genetical Recombination)ペルツズマブ（遺伝子組換え）・トラスツズマブ（遺伝子組換え）・ボルヒアルロニダーゼ　アルファ（遺伝子組換え）Polatuzumab Vedotin (Genetical Recombination)ポラツズマブ　ベドチン（遺伝子組換え）PomalidomideポマリドミドPrasugrel Hydrochlorideプラスグレル塩酸塩Purified Sodium Hyaluronate精製ヒアルロン酸ナトリウムRamucirumab (Genetical Recombination)ラムシルマブ（遺伝子組換え）Ravulizumab (Genetical Recombination)ラブリズマブ（遺伝子組換え）RebamipideレバミピドRemdesivirレムデシビルRisankizumab (Genetical Recombination)リサンキズマブ（遺伝子組換え）RivaroxabanリバーロキサバンRomosozumab (Genetical Recombination)ロモソズマブ（遺伝子組換え）Rosuvastatin CalciumロスバスタチンカルシウムRuxolitinib Phosphateルキソリチニブリン酸塩Sacubitril Valsartan Sodium Hydrateサクビトリルバルサルタンナトリウム水和物Satralizumab (Genetical Recombination)サトラリズマブ（遺伝子組換え）Semaglutide (Genetical Recombination)セマグルチド（遺伝子組換え）Sitagliptin Phosphate Hydrateシタグリプチンリン酸塩水和物Somatropin (Genetical Recombination)ソマトロピン（遺伝子組換え）Tacrolimus Hydrateタクロリムス水和物TafamidisタファミジスTeneligliptin Hydrobromide Hydrateテネリグリプチン臭化水素酸塩水和物Teriparatide Acetateテリパラチド酢酸塩TirzepatideチルゼパチドTocilizumab (Genetical Recombination)トシリズマブ（遺伝子組換え）TolvaptanトルバプタンTrastuzumab Deruxtecan (Genetical Recombination)トラスツズマブ　デルクステカン（遺伝子組換え）Upadacitinib Hydrateウパダシチニブ水和物Ustekinumab (Genetical Recombination)ウステキヌマブ（遺伝子組換え）VibegronビベグロンVilanterol Trifenatate / Fluticasone Furoateビランテロールトリフェニル酢酸塩・フルチカゾンフランカルボン酸エステルVonoprazan Fumarateボノプラザンフマル酸塩

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

Contact us

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.